Vebreltinib before surgery for MET-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called vebreltinib before surgery for people with a specific type of lung cancer (MET exon 14 skipping mutation) that is at a stage where it can be removed. The goal is to see if the drug can shrink the tumor before surgery, making the operation more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) with a specific genetic change called MET exon 14 skipping.
- Your cancer is at a stage where it can be removed with surgery (Stage IIA to IIIB, with N2 involvement).
- You are at least 18 years old and in generally good health, able to do daily activities without help.
- You have not had any prior targeted therapy, immunotherapy, or experimental drugs for your lung cancer.
- You are willing to use effective birth control during and for a period after the study if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This trial tests a combination of two drugs (SHR-A1811 and Adebelimumab) given before surgery for people with a specific type of lung cancer that has changes in the HER2 gene. The goal is to see if this treatment can shrink the tumor and make surgery more effective.
This trial tests a new drug called vebreltinib combined with standard chemotherapy for advanced non-small cell lung cancer (a common type of lung cancer) in patients whose tumors show high levels of a protein called MET. The goal is to see if this combination can slow cancer growth better than chemotherapy alone.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.